<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Arial,Italic" color="#000000"/>
	<fontspec id="font1" size="9" family="Arial" color="#000000"/>
	<fontspec id="font2" size="9" family="Arial,Bold" color="#000000"/>
	<fontspec id="font3" size="7" family="Arial,Italic" color="#000000"/>
	<fontspec id="font4" size="10" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font5" size="11" family="GillSans,Bold" color="#000000"/>
	<fontspec id="font6" size="9" family="GillSans,BoldItalic" color="#000000"/>
	<fontspec id="font7" size="10" family="Symbol" color="#000000"/>
<text top="41" left="55" width="208" height="10" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="title"><i>Current Controlled Trials in Cardiovascular Medicine</i></text>
<text top="41" left="263" width="27" height="10" font="font1" id="p1_t2" reading_order_no="1" segment_no="0" tag_type="title"> 2005, </text>
<text top="41" left="291" width="5" height="10" font="font2" id="p1_t3" reading_order_no="2" segment_no="0" tag_type="title"><b>6</b></text>
<text top="41" left="296" width="13" height="10" font="font1" id="p1_t4" reading_order_no="3" segment_no="0" tag_type="title">:15</text>
<text top="41" left="373" width="181" height="10" font="font1" id="p1_t5" reading_order_no="4" segment_no="1" tag_type="text">http://cvm.controlled-trials.com/content/6/1/15</text>
<text top="756" left="508" width="46" height="10" font="font1" id="p1_t6" reading_order_no="111" segment_no="15" tag_type="text">Page 3 of 9</text>
<text top="769" left="432" width="122" height="8" font="font3" id="p1_t7" reading_order_no="112" segment_no="16" tag_type="text"><i>(page number not for citation purposes)</i></text>
<text top="87" left="55" width="241" height="9" font="font4" id="p1_t8" reading_order_no="5" segment_no="2" tag_type="text">clinicians believe in the beneficial effects of clopidogrel,</text>
<text top="98" left="55" width="241" height="9" font="font4" id="p1_t9" reading_order_no="6" segment_no="2" tag_type="text">the increased risk of bleeding and the lack of data in CABG</text>
<text top="110" left="55" width="241" height="9" font="font4" id="p1_t10" reading_order_no="7" segment_no="2" tag_type="text">patients make it impossible to establish definitive recom-</text>
<text top="122" left="55" width="241" height="9" font="font4" id="p1_t11" reading_order_no="8" segment_no="2" tag_type="text">mendations. We therefore propose the Clopidogrel after</text>
<text top="134" left="55" width="241" height="9" font="font4" id="p1_t12" reading_order_no="9" segment_no="2" tag_type="text">Surgery for Coronary Artery Disease (CASCADE) study, a</text>
<text top="145" left="55" width="241" height="9" font="font4" id="p1_t13" reading_order_no="10" segment_no="2" tag_type="text">randomized, placebo-controlled trial comparing clopi-</text>
<text top="157" left="55" width="241" height="9" font="font4" id="p1_t14" reading_order_no="11" segment_no="2" tag_type="text">dogrel plus aspirin versus aspirin alone in CABG patients</text>
<text top="169" left="55" width="241" height="9" font="font4" id="p1_t15" reading_order_no="12" segment_no="2" tag_type="text">revascularized with saphenous vein. The primary aim of</text>
<text top="181" left="55" width="241" height="9" font="font4" id="p1_t16" reading_order_no="13" segment_no="2" tag_type="text">this study will be to evaluate the effect of combined</text>
<text top="192" left="55" width="241" height="9" font="font4" id="p1_t17" reading_order_no="14" segment_no="2" tag_type="text">antiplatelet therapy on the reduction of SVG intimal</text>
<text top="204" left="55" width="241" height="9" font="font4" id="p1_t18" reading_order_no="15" segment_no="2" tag_type="text">hyperplasia one year after CABG, through the assessment</text>
<text top="216" left="55" width="241" height="9" font="font4" id="p1_t19" reading_order_no="16" segment_no="2" tag_type="text">of intimal area by intravascular ultrasound (IVUS). Sec-</text>
<text top="228" left="55" width="241" height="9" font="font4" id="p1_t20" reading_order_no="17" segment_no="2" tag_type="text">ondary aims will evaluate the safety of clopidogrel admin-</text>
<text top="239" left="55" width="241" height="9" font="font4" id="p1_t21" reading_order_no="18" segment_no="2" tag_type="text">istration following CABG with regards to bleeding</text>
<text top="251" left="55" width="241" height="9" font="font4" id="p1_t22" reading_order_no="19" segment_no="2" tag_type="text">complications. We hypothesize that the combination of</text>
<text top="263" left="55" width="241" height="9" font="font4" id="p1_t23" reading_order_no="20" segment_no="2" tag_type="text">clopidogrel with aspirin will reduce the SVG intimal</text>
<text top="275" left="55" width="241" height="9" font="font4" id="p1_t24" reading_order_no="21" segment_no="2" tag_type="text">hyperplasia (intimal area) by 20% one year post-CABG</text>
<text top="286" left="55" width="241" height="9" font="font4" id="p1_t25" reading_order_no="22" segment_no="2" tag_type="text">compared to the usual antiplatelet therapy of aspirin</text>
<text top="298" left="55" width="26" height="9" font="font4" id="p1_t26" reading_order_no="23" segment_no="2" tag_type="text">alone.</text>
<text top="322" left="55" width="43" height="10" font="font5" id="p1_t27" reading_order_no="24" segment_no="5" tag_type="title"><b>Methods</b></text>
<text top="334" left="55" width="189" height="9" font="font6" id="p1_t28" reading_order_no="25" segment_no="6" tag_type="title"><i><b>Study Population and Recruitment Procedure</b></i></text>
<text top="345" left="55" width="241" height="9" font="font4" id="p1_t29" reading_order_no="26" segment_no="7" tag_type="text">The study population will include all patients undergoing</text>
<text top="357" left="55" width="241" height="9" font="font4" id="p1_t30" reading_order_no="27" segment_no="7" tag_type="text">multi-vessel elective or urgent CABG using at least two</text>
<text top="369" left="55" width="241" height="9" font="font4" id="p1_t31" reading_order_no="28" segment_no="7" tag_type="text">saphenous vein grafts at the University of Ottawa Heart</text>
<text top="380" left="55" width="241" height="9" font="font4" id="p1_t32" reading_order_no="29" segment_no="7" tag_type="text">Institute (OHI) over the study period (see <a href="">Table 1 for</a></text>
<text top="392" left="55" width="241" height="9" font="font4" id="p1_t33" reading_order_no="30" segment_no="7" tag_type="text">inclusion and exclusion criteria). Patients undergoing off-</text>
<text top="404" left="55" width="241" height="9" font="font4" id="p1_t34" reading_order_no="31" segment_no="7" tag_type="text">pump CABG (OPCAB) will also be eligible for this study,</text>
<text top="416" left="55" width="241" height="9" font="font4" id="p1_t35" reading_order_no="32" segment_no="7" tag_type="text">as long as at least two saphenous vein grafts are used.</text>
<text top="427" left="55" width="241" height="9" font="font4" id="p1_t36" reading_order_no="33" segment_no="7" tag_type="text">OPCAB is performed in order to avoid the hazards associ-</text>
<text top="439" left="55" width="241" height="9" font="font4" id="p1_t37" reading_order_no="34" segment_no="7" tag_type="text">ated with standard CABG, such as cardiopulmonary</text>
<text top="451" left="55" width="241" height="9" font="font4" id="p1_t38" reading_order_no="35" segment_no="7" tag_type="text">bypass and aortic cross-clamping, and is carried out at the</text>
<text top="463" left="55" width="241" height="9" font="font4" id="p1_t39" reading_order_no="36" segment_no="7" tag_type="text">discretion of the surgeon in patients deemed to be at</text>
<text top="474" left="55" width="241" height="9" font="font4" id="p1_t40" reading_order_no="37" segment_no="7" tag_type="text">higher risk of thromboembolic or renal complications</text>
<text top="486" left="55" width="241" height="9" font="font4" id="p1_t41" reading_order_no="38" segment_no="7" tag_type="text">during surgery. All CABG patients at the OHI will be</text>
<text top="498" left="55" width="241" height="9" font="font4" id="p1_t42" reading_order_no="39" segment_no="7" tag_type="text">triaged pre-operatively, and study eligible patients will be</text>
<text top="510" left="55" width="241" height="9" font="font4" id="p1_t43" reading_order_no="40" segment_no="7" tag_type="text">selected and approached by the study nurse to explain the</text>
<text top="521" left="55" width="103" height="9" font="font4" id="p1_t44" reading_order_no="41" segment_no="7" tag_type="text">trial and obtain consent.</text>
<text top="545" left="55" width="165" height="9" font="font6" id="p1_t45" reading_order_no="42" segment_no="12" tag_type="title"><i><b>Description of Intervention and Control</b></i></text>
<text top="557" left="55" width="241" height="9" font="font4" id="p1_t46" reading_order_no="43" segment_no="13" tag_type="text">A prospective randomized double-blinded placebo-con-</text>
<text top="568" left="55" width="241" height="9" font="font4" id="p1_t47" reading_order_no="44" segment_no="13" tag_type="text">trolled study will be conducted from November 2005 to</text>
<text top="580" left="55" width="241" height="9" font="font4" id="p1_t48" reading_order_no="45" segment_no="13" tag_type="text">November 2007 in order to achieve the study objectives.</text>
<text top="592" left="55" width="241" height="9" font="font4" id="p1_t49" reading_order_no="46" segment_no="13" tag_type="text">Patients will be recruited over the first 12 months of the</text>
<text top="604" left="55" width="241" height="9" font="font4" id="p1_t50" reading_order_no="47" segment_no="13" tag_type="text">study, and graft evaluation for each patient will occur over</text>
<text top="615" left="55" width="241" height="9" font="font4" id="p1_t51" reading_order_no="48" segment_no="13" tag_type="text">the following 12 months (one year after surgery for each</text>
<text top="627" left="55" width="241" height="9" font="font4" id="p1_t52" reading_order_no="49" segment_no="13" tag_type="text">patient). Patients will be randomized into an experimen-</text>
<text top="639" left="55" width="241" height="9" font="font4" id="p1_t53" reading_order_no="50" segment_no="13" tag_type="text">tal group (receiving clopidogrel) or a control group (pla-</text>
<text top="651" left="55" width="241" height="9" font="font4" id="p1_t54" reading_order_no="51" segment_no="13" tag_type="text">cebo). The placebo and clopidogrel medications will be</text>
<text top="662" left="55" width="241" height="9" font="font4" id="p1_t55" reading_order_no="52" segment_no="13" tag_type="text">prepared by the Bristol Myers-squibb Sanofi Canada Part-</text>
<text top="674" left="55" width="241" height="9" font="font4" id="p1_t56" reading_order_no="53" segment_no="13" tag_type="text">nership and appear identical. Medication administration</text>
<text top="686" left="55" width="241" height="9" font="font4" id="p1_t57" reading_order_no="54" segment_no="13" tag_type="text">and data collection will be performed in a double-blind</text>
<text top="698" left="55" width="241" height="9" font="font4" id="p1_t58" reading_order_no="55" segment_no="13" tag_type="text">manner, such that neither the patient nor the healthcare</text>
<text top="709" left="55" width="241" height="9" font="font4" id="p1_t59" reading_order_no="56" segment_no="13" tag_type="text">personnel will be aware of the medication assignment.</text>
<text top="721" left="55" width="241" height="9" font="font4" id="p1_t60" reading_order_no="57" segment_no="13" tag_type="text">Recruitment and written consent will be performed prior</text>
<text top="87" left="313" width="241" height="9" font="font4" id="p1_t61" reading_order_no="58" segment_no="3" tag_type="text">to surgery. However, patients will not be randomized</text>
<text top="98" left="313" width="241" height="9" font="font4" id="p1_t62" reading_order_no="59" segment_no="3" tag_type="text">until after surgery has been completed and clinical stabil-</text>
<text top="110" left="313" width="241" height="9" font="font4" id="p1_t63" reading_order_no="60" segment_no="3" tag_type="text">ity ensured. Patients that are bleeding excessively after sur-</text>
<text top="122" left="313" width="241" height="9" font="font4" id="p1_t64" reading_order_no="61" segment_no="3" tag_type="text">gery (chest tube output &gt; 200 cc/hr) or those requiring</text>
<text top="134" left="313" width="241" height="9" font="font4" id="p1_t65" reading_order_no="62" segment_no="3" tag_type="text">high levels of hemodynamic support (more than 2 ino-</text>
<text top="145" left="313" width="241" height="9" font="font4" id="p1_t66" reading_order_no="63" segment_no="3" tag_type="text">tropes and/or intra-aortic balloon pump) will not be ran-</text>
<text top="157" left="313" width="101" height="9" font="font4" id="p1_t67" reading_order_no="64" segment_no="3" tag_type="text">domized into the study.</text>
<text top="181" left="313" width="241" height="9" font="font4" id="p1_t68" reading_order_no="65" segment_no="4" tag_type="text">After surgery, the study medication will be administered</text>
<text top="192" left="313" width="241" height="9" font="font4" id="p1_t69" reading_order_no="66" segment_no="4" tag_type="text">via nasogastric tube when the chest tube drainage has</text>
<text top="204" left="313" width="59" height="9" font="font4" id="p1_t70" reading_order_no="67" segment_no="4" tag_type="text">decreased to </text>
<text top="202" left="372" width="5" height="13" font="font7" id="p1_t71" reading_order_no="68" segment_no="4" tag_type="text">≤</text>
<text top="204" left="378" width="176" height="9" font="font4" id="p1_t72" reading_order_no="69" segment_no="4" tag_type="text">50 cc/hr for 2 hours. Each patient will</text>
<text top="216" left="313" width="241" height="9" font="font4" id="p1_t73" reading_order_no="70" segment_no="4" tag_type="text">receive either clopidogrel 75 mg or placebo, in addition to</text>
<text top="228" left="313" width="241" height="9" font="font4" id="p1_t74" reading_order_no="71" segment_no="4" tag_type="text">enteric coated aspirin 162 mg (Fig<a href="">ure 1</a>). The study drug</text>
<text top="239" left="313" width="241" height="9" font="font4" id="p1_t75" reading_order_no="72" segment_no="4" tag_type="text">and aspirin 162 mg will be repeated orally in the same</text>
<text top="251" left="313" width="241" height="9" font="font4" id="p1_t76" reading_order_no="73" segment_no="4" tag_type="text">dose once daily for the duration of one year. Because post-</text>
<text top="263" left="313" width="241" height="9" font="font4" id="p1_t77" reading_order_no="74" segment_no="4" tag_type="text">CABG patients are relatively aspirin resistant following</text>
<text top="275" left="313" width="241" height="9" font="font4" id="p1_t78" reading_order_no="75" segment_no="4" tag_type="text">surgery, the aspirin dose of 162 mg will ensure adequate</text>
<text top="286" left="313" width="241" height="9" font="font4" id="p1_t79" reading_order_no="76" segment_no="4" tag_type="text">platelet inhibition in those patients randomized to aspi-</text>
<text top="298" left="313" width="241" height="9" font="font4" id="p1_t80" reading_order_no="77" segment_no="4" tag_type="text">rin alone. Furthermore, 162 mg falls within the safety</text>
<text top="310" left="313" width="241" height="9" font="font4" id="p1_t81" reading_order_no="78" segment_no="4" tag_type="text">window of combining aspirin with clopidogrel</text>
<text top="322" left="313" width="47" height="9" font="font4" id="p1_t82" reading_order_no="79" segment_no="4" tag_type="text">[<a href="">30,40,44]</a>.</text>
<text top="345" left="313" width="87" height="9" font="font6" id="p1_t83" reading_order_no="80" segment_no="8" tag_type="title"><i><b>Allocation Procedure</b></i></text>
<text top="357" left="313" width="241" height="9" font="font4" id="p1_t84" reading_order_no="81" segment_no="9" tag_type="text">A stratified random design allocation will be utilized to</text>
<text top="369" left="313" width="241" height="9" font="font4" id="p1_t85" reading_order_no="82" segment_no="9" tag_type="text">account for the presence or absence of diabetes, as well as</text>
<text top="380" left="313" width="241" height="9" font="font4" id="p1_t86" reading_order_no="83" segment_no="9" tag_type="text">the use or nonuse of cardiopulmonary bypass (standard</text>
<text top="392" left="313" width="241" height="9" font="font4" id="p1_t87" reading_order_no="84" segment_no="9" tag_type="text">CABG versus OPCAB). A block randomization technique</text>
<text top="404" left="313" width="241" height="9" font="font4" id="p1_t88" reading_order_no="85" segment_no="9" tag_type="text">will ensure an equal distribution of diabetic patients in</text>
<text top="416" left="313" width="241" height="9" font="font4" id="p1_t89" reading_order_no="86" segment_no="9" tag_type="text">both arms of the trial and an equal distribution of OPCAB</text>
<text top="427" left="313" width="241" height="9" font="font4" id="p1_t90" reading_order_no="87" segment_no="9" tag_type="text">patients. The randomization schedule will be generated</text>
<text top="439" left="313" width="241" height="9" font="font4" id="p1_t91" reading_order_no="88" segment_no="9" tag_type="text">using SAS 9.1 software (SAS, Cary, NC). All patients and</text>
<text top="451" left="313" width="241" height="9" font="font4" id="p1_t92" reading_order_no="89" segment_no="9" tag_type="text">study personnel will be blinded to the treatment assign-</text>
<text top="463" left="313" width="241" height="9" font="font4" id="p1_t93" reading_order_no="90" segment_no="9" tag_type="text">ment, which will be performed by the hospital pharmacy.</text>
<text top="486" left="313" width="174" height="9" font="font6" id="p1_t94" reading_order_no="91" segment_no="10" tag_type="title"><i><b>Concomitant Medication and Treatments</b></i></text>
<text top="498" left="313" width="241" height="9" font="font4" id="p1_t95" reading_order_no="92" segment_no="11" tag_type="text">Patients will receive concomitant therapies in both groups</text>
<text top="510" left="313" width="241" height="9" font="font4" id="p1_t96" reading_order_no="93" segment_no="11" tag_type="text">as recommended by the current American College of Car-</text>
<text top="521" left="313" width="241" height="9" font="font4" id="p1_t97" reading_order_no="94" segment_no="11" tag_type="text">diology / American Heart Association guidelines. This will</text>
<text top="533" left="313" width="241" height="9" font="font4" id="p1_t98" reading_order_no="95" segment_no="11" tag_type="text">include smoking cessation counseling and the administra-</text>
<text top="545" left="313" width="241" height="9" font="font4" id="p1_t99" reading_order_no="96" segment_no="11" tag_type="text">tion of aspirin, beta blockers, angiotensin converting</text>
<text top="557" left="313" width="241" height="9" font="font4" id="p1_t100" reading_order_no="97" segment_no="11" tag_type="text">enzyme inhibitors, and lipid lowering medications. Target</text>
<text top="568" left="313" width="241" height="9" font="font4" id="p1_t101" reading_order_no="98" segment_no="11" tag_type="text">LDL values will be those recommended as per current</text>
<text top="580" left="313" width="241" height="9" font="font4" id="p1_t102" reading_order_no="99" segment_no="11" tag_type="text">guidelin<a href="">es [45-47] and will be</a> assessed during the study</text>
<text top="592" left="313" width="241" height="9" font="font4" id="p1_t103" reading_order_no="100" segment_no="11" tag_type="text">follow-up period. Routine peptic ulcer prophylaxis will</text>
<text top="604" left="313" width="241" height="9" font="font4" id="p1_t104" reading_order_no="101" segment_no="11" tag_type="text">not be administered in order to fully evaluate gastrointes-</text>
<text top="615" left="313" width="70" height="9" font="font4" id="p1_t105" reading_order_no="102" segment_no="11" tag_type="text">tinal side effects.</text>
<text top="639" left="313" width="241" height="9" font="font4" id="p1_t106" reading_order_no="103" segment_no="14" tag_type="text">Diabetic patients will be eligible for enrollment in this</text>
<text top="651" left="313" width="241" height="9" font="font4" id="p1_t107" reading_order_no="104" segment_no="14" tag_type="text">study, regardless of their preoperative need for insulin</text>
<text top="662" left="313" width="241" height="9" font="font4" id="p1_t108" reading_order_no="105" segment_no="14" tag_type="text">therapy, and will be allocated equally into both groups</text>
<text top="674" left="313" width="241" height="9" font="font4" id="p1_t109" reading_order_no="106" segment_no="14" tag_type="text">through stratified randomization. Diabetic patients will</text>
<text top="686" left="313" width="241" height="9" font="font4" id="p1_t110" reading_order_no="107" segment_no="14" tag_type="text">have aggressive perioperative glycemic control, including</text>
<text top="698" left="313" width="241" height="9" font="font4" id="p1_t111" reading_order_no="108" segment_no="14" tag_type="text">an intravenous insulin infusion both in the operating</text>
<text top="709" left="313" width="241" height="9" font="font4" id="p1_t112" reading_order_no="109" segment_no="14" tag_type="text">room and in the intensive care unit, and a subcutaneous</text>
<text top="721" left="313" width="241" height="9" font="font4" id="p1_t113" reading_order_no="110" segment_no="14" tag_type="text">insulin sliding scale while recovering on the surgical ward.</text>
</page>
</pdf2xml>
